Compare TotalEnergies SE (TTE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TotalEnergies SE vs State Street SPDR S&P Biotech ETF — how do they compare? TotalEnergies SE trades at $86.97 (market cap $191.82B), while State Street SPDR S&P Biotech ETF trades at $154 (market cap $10.11B). The key difference: TotalEnergies SE is far larger — about 19× State Street SPDR S&P Biotech ETF's market cap, and TotalEnergies SE pays a 4.93% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold TotalEnergies SE for 90 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| TTE | XBI | |
|---|---|---|
Market Cap | $191.82B | $10.11B |
Volume | 3,311,339 | 12,903,266 |
Sector | Energy | Broad Market / Factor |
52-Week High | $93.60 | $169.55 |
52-Week Low | $57.39 | $104.99 |
Typical Hold Time | 90 Days | 38 Days |
Enterprise Value | $222.81B | — |
Dividend Yield | 4.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TotalEnergies (TTE) trades at $87.25, up 3.59% today, with a bearish technical signal but strong fundamentals including a low P/E of 10.77 and robust cash flow. Recent earnings beat expectations in Q1 and Q2 2026, while the company announced a $10 billion investment in Argentina and plans for dividend growth through 2030, signaling strategic expansion.
The outlook is positive with analyst consensus at Buy and a $95.33 price target, though risks include declining revenue trends and geopolitical exposure. Upside potential hinges on execution of growth initiatives and energy price stability, while investor sentiment remains supported by shareholder returns.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
